An Open-Label 52-Week Clinical Extension Comparing Duloxetine with Routine Care in Patients with Diabetic Peripheral Neuropathic Pain
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP). DESIGN AND INTERVENTIONS: Patients who completed a 13-week, randomized, double-blind, placebo-controlled acute therapy period were randomly reassigned in a 2:1 ratio to therapy with duloxetine 60 mg BID (N = 197) or routine care (N = 96) for an additional 52 weeks. PATIENTS: The trial included outpatients > or =18 years of age diagnosed with moderate to severe DPNP caused by type 1 or type 2 diabetes. RESULTS: Fourteen patients discontinued due to adverse events or death (11 [5.6%] duloxetine- and 3 [3.1%] routine care-treated patients). There were no significant therapy-group differences observed for patients with >/=1 serious adverse event. In total, 110 (55.8%) duloxetine- and 47 (49%) routine care-treated patients had > or =1 treatment-emergent adverse event (TEAE). The TEAE with a significant therapy-group difference, with patients in the duloxetine therapy group experiencing a higher percentage of events, was asthenia (11 [5.6%] duloxetine- vs no routine care-treated patients). Duloxetine did not appear to adversely affect lipid profiles, or nerve or eye function. There were no significant therapy-group differences observed in mean change in systolic blood pressure, weight, or electrocardiogram parameters. Significant therapy-group differences were observed in favor of duloxetine in the SF-36 physical component summary score, and subscale scores of physical functioning, bodily pain, mental health, and vitality. CONCLUSIONS: The results of this study provide support for the use of duloxetine in the long-term management of DPNP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain
Courteix, C., Eschalier, A., & Lavarenne, J. (1993) · Pain · doi:10.1016/0304-3959(93)90059-x · Cited by 454
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Cited by
Sultan, A., Gaskell, H., Derry, S., & Moore, R. A. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-29 · Cited by 291
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54
Self-citationYasuda, H., Hotta, N., Kasuga, M., Kashiwagi, A., Kawamori, R., Yamada, T., Baba, Y., Alev, L., & Nakajo, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12361 · Cited by 27
Zhao, Y., Liu, J., Zhao, Y., Thethi, T., Fonseca, V., & Shi, L. (2012) · Pain Practice · doi:10.1111/j.1533-2500.2011.00494.x · Cited by 10
Metadata
- Authors
- Wernicke, J. F., Wang, F., Pritchett, Y. L., Smith, T. R., Raskin, J., D'Souza, D. N., Iyengar, S., & Chappell, A. S.
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09
- Volume
- 8
- Issue
- 6
- Pages
- 503-513
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- OpenAlex
- W2146594973
- Cited by
- 59
- References
- 6
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.